newsfilter
← Latest News
GlobeNewswire·

AEON Biopharma Announces Fundraise Totaling Up to ~$22 Million through Private Placement and Proposed Exchange of Daewoong Convertible Notes

  • AEON Biopharma announced two transactions totaling up to ~$22 million in potential proceeds to strengthen its balance sheet & reduce outstanding debt by over 90%.
  • The company entered a securities purchase agreement for a $6 million PIPE financing with two existing investors, with potential for over $7 million in additional capital via cash-exercise warrants.
  • AEON & Daewoong Pharmaceutical agreed to a binding term sheet to exchange $15 million of convertible notes plus accrued interest for approximately 23.1 million shares, a $1.5 million new note due 2030, & 8 million cash-exercise warrants totaling over $8 million in potential proceeds.
  • Proceeds from these transactions are expected to extend AEON's cash runway into the second quarter of 2026 & accelerate the ABP-450 biosimilar program by up to six months.
  • The transactions support the uninterrupted advancement of the ABP-450 biosimilar program following positive analytical data submitted to the FDA ahead of an upcoming Type 2a meeting.
  • The first PIPE closing is expected in November 2025 for $1.79 million in gross proceeds, subject to customary conditions, while the second closing requires stockholder approval & completion of the Daewoong note exchange.
  • The Daewoong note exchange will transform AEON's capital structure & strengthen long-term strategic alignment, pending definitive documentation & stockholder approval.